logo-loader
viewFutura Medical PLC

Futura Medical provides update on commercial progress with breakthrough gel

The company has developed a fast-acting erectile dysfunction product that could be sold over the counter

Futura Medical PLC -
The company is likely to have to fulfill additional data requirements before the watchdog is ready to press the approval button

Futura Medical PLC (LON:FUM) has said it is “actively engaged” in commercial discussions about its erectile dysfunction (ED) gel ahead of a key meeting with US regulators.

The company said it has hired corporate advisers to organise the interaction with potential licensing and marketing partners for MED3000. It believes there is scope for the new treatment to become an over the counter (OTC) product, tapping into a large unmet need.

It is estimated that at least half of men with ED do not consult a doctor and, therefore, are not prescribed treatment. At the same time, pills such as Viagra and Cialis are not widely available over the counter. The UK is one of the few exceptions with Viagra Connect.

"We are increasingly excited by the commercial potential for MED3000 as the first, clinically proven treatment for erectile dysfunction that is highly differentiated with its rapid speed of onset and may be available without the need of a doctor's prescription bringing accessibility to men throughout the EU and US,” Futura chief executive James Barder said in a statement.

“This sentiment is shared with a number of potential commercial partners with whom we are now actively engaged in discussions."

He added that a meeting has been arranged with the US Food & Drug Administration “before the end of October” at which the company expects to agree “the final outstanding data requirements” to gain regulatory approval for MED3000 as an OTC treatment in the United States.

Futura said it would update the market on the interaction with the regulator following the pre-submission meeting.

The progress report was provided as part of Futura’s interim results statement in which it was revealed the company had, as at June 30, 2020, cash reserves of £2.62mln. This is enough to see Futura through to the second quarter of 2021 under current plans.

As is the norm for companies investing heavily in research and development, Futura was loss-making in the first half. It made a net loss of just over £1mln.

Quick facts: Futura Medical PLC

Price: 15.5 GBX

AIM:FUM
Market: AIM
Market Cap: £38.07 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical gets set to begin formal approval steps for erectile...

Futura Medical PLC’s (LON:FUR) James Barder talks to Proactive London’s Katie Pilbeam about the highlights in their half-year report which includes the latest on MED3000 - a topical treatment for Erectile Dysfunction. Proceedings have begun for formal approval of the drug to be approved as a...

4 days, 3 hours ago

2 min read